Israeli Firm Leads Investment in COVID-19 Vaccine

April 23, 2020

MigVax, an affiliate of the Migal Galilee Research Institute in Israel, is developing a vaccine candidate for COVID-19.

The company previously developed a vaccine against infectious bronchitis virus, a coronavirus strain that causes bronchial disease in poultry.

The Israel-based OurCrowd is leading a $12 million investment in a human vaccine development program.

View today's stories